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Introduction: Extracorporeal shock wave treatment (ESWT) has recently been shown to enhance skin ﬂap
survival. However, the bio-mechanisms operating during preoperative ESWT remain unclear. The aim of
our study was to investigate whether preoperative ESWT can improve blood ﬂow in ischemic skin ﬂaps
and to elucidate its possible mechanisms.
Methods: 14 male-rats were randomized into two groups and an oversized ventral random-pattern ﬂap
was raised. Experimental group received extracorporeal shock-wave treatment (ESWT) with an energy of
500 mJ/mm2 seven days prior to total ﬂap elevation, while control group received no treatment prior to
total ﬂap elevation. Seven days postoperatively, surviving ﬂap area, perfused ﬂap area, microvessel
density and VEGF concentration were measured.
Results: Surviving ﬂap area (59.43  14.72 % to 42.71  10.75 %, p ¼ 0.026), perfused ﬂap area
(62.00  8.58 % to 45.14  10.50 %, p ¼ 0.007), microvessel density (18.13  5.11 to 11.09  1.12, p ¼ 0.016)
and VEGF to total protein ratio (0.2107  0.0935 to 0.0123  0.0069, p ¼ 0.008) were signiﬁcantly
elevated in the ESWT group.
Conclusion: Preoperative ESWT can improve skin ﬂap survival through enhanced topical blood perfusion
and neovascularization via elevation of angio-active factors.
 2011 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Avariety ofmethods have been described to ameliorate ischemic
necrosis in the distal part of failing skin ﬂaps such as surgical delay,
ischemic preconditioning, hyperthermia, hypothermia, drugs and
growth factors.1e5 All these physical and pharmacological measures
seem to have in common that they expose the tissue to a sublethal
degree of environmental stress and render tissue more resistant
to further ischemia. However, potential side effects, invasive
administration, additional surgical intervention or an unfavorable
cost-effectiveness ratio are associated with these treatments.
Extracorporeal Shock Wave Treatment (ESWT) is known for its
lithotripsy applications in the ﬁeld of urology, but has been adopted
and applied for many other indications such as musculoskeletal
disorders.6e12 ESWTeffectively induced angiogenesis and improved.A. Reichenberger).
ciates Ltd. Published by Elsevier Ltchronic ischemia in animals and humans.13e17 Subsequent studies
demonstrated an improved skin ﬂap survival in rodent model,
associated with a signiﬁcant rise of growth factors such as vascular
growth endothelial factor (VEGF), endothelial nitric oxide synthase
and proliferating cell nuclear antigen (PNCA) after ESW treat-
ment.18,19 In all of these studies ESWwas applied immediately after
the surgical intervention. Previously we were be able to show that
preoperative ESWT enhance skin ﬂap survival in ischemia-chal-
lenged skin ﬂaps in rats.20 Because of limitations of our experi-
mental design, the bio-mechanisms operating during preoperative
ESWT remained unclear. Therefore, this study aimed at elucidating
the effect of preoperative ESWTon blood ﬂow in ischemic skin ﬂaps
and its possible mechanisms.
2. Methods
2.1. Animals
All experiments were performed in accordance with the guidelines of the
German Animal Welfare Act and the experimental protocol was approved byd. All rights reserved.
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housed under conventional conditions.
2.2. Experimental design
A total of 14 male Wistar rats weighing 290e350 g each were used in this study.
In all experiments anesthesia was induced and maintained by intraperitoneal
injection of 100 mg/kg ketamine hydrochloride (Ketamin 100 mg/mL Gräub, ani-
Medica GmbH, Senden-Bösensell, Germany) and 5 mg/kg xylazine (Xylazin 2%,
Riemser Arzneimittel, Greifswald, Germany). The abdominal area was shaved with
an electric razor and after marking the borders of the skin ﬂap all animals were
randomly divided into one of the two groups (n ¼ 7 in each group) (Table 1).
2.3. ESWT
In the ESWT-Group all animals were treated with a single application of ESWT 7
days prior to full skin ﬂap harvest. Appliance of ESWT was performed with 500
impulses at 0.15 mJ/mm2 (dermaPACE, Sanuwave Inc., Alpharetta, GA, USA) as
a single treatment. Ultrasound transmission gel (Sonogel, Bad Camberg, Germany)
was used as a contact medium between the ESW apparatus and skin. The ESWT
applicator of 4 cm diameter was positioned perpendicular to the distal half of the
ﬂap, because this area represents the ischemic portion of the ﬂap that predictably
undergoes necrosis. The applicator was randomlymoved to cover full size of the ﬂap.
Dosage and means of application of ESWT were based on previous studies and
recommendations by the manufacturer.18,20e22
2.4. Surgery
The surgical procedure was performed by one surgeon (HK) on all animals and
was identical for all groups. Prior to any other treatment, all animals were re-
anesthetized and the abdominal area was shaved with an electric razor and
prepared with Octenisept (Schülke & Mayr, Norderstedt, Germany). A cranially
based cutaneous ﬂap (8  2 cm) was outlined with the medial margin running from
the xiphoid 8 cm caudally, which results in a length-to-width ratio of 1:4. This ﬂap
design results in necrosis in the distal portion of the ﬂap due to insufﬁcient perfu-
sion.2,23,24 The ﬂap was then placed onto a silicone sheet (Mepiform, Mölnlycke
Health Care, Erkrath-Unterfeldhaus, Germany) to prevent nutrition by diffusion
from the wound bed and sutured back using 4-0 polypropylene sutures (Prolene,
Johnson & Johnson Medical, Norderstedt, Germany).
2.5. Post-operative management
Post-operative analgesia was achieved by daily subcutaneous injection of
5 mg/kg Carprofen (Rimadyl, Pﬁzer, Berlin, Germany). All animals were observed
daily. Seven days after ﬂap harvesting, full-thickness necrosis was fully developed in
each rat. Animals were re-anesthetized and follow-up evaluations were performed.
2.6. Skin ﬂap survival
With a clear demarcation in the distal part of the ﬂap, standardized digital
pictures of the abdominal wall were taken perpendicular to the ﬂap and transferred
to the computer. The mean area of ﬂap necrosis, deﬁned by surgical borders
(expressed as a percentage of the total ﬂap area) was calculated for each animal
using ImageJ-Software (NIH, USA). The results were expressed as percentage relative
to the surface area of the total ﬂap.
2.7. Indocyanine green laser-ﬂuoroscopy (ICG)
Indocyanine green-ﬂuorescence was induced and recorded using a laser-ﬂuo-
rescence imaging device (IC-View, PulsionMedical Systems AG, Munich, Germany),
comprising a NIR laser light source (0.16 W, wavelength â ¼ 780 nm) and a NIR-
ﬁltered digital camcorder. All animals received an injection (indocyanine) of
0.3 mg/kg bodyweight into the penis vein. Afterward, ﬂuorescence was recorded
with a digital camera producing gray scale images that were transferred to an image
analyzing system (ImageJ, NIH, USA). The perfused areawas expressed as percentage
relative to total area of the ﬂap.Table 1
Summary of statistical values.
Surviving area Perfused area
n n
Control 7 42.71  10.75% 7 45.14  10.50
ESWT 7 59.43  14.72% 7 62.00  8.58%
p 0.026 0.007
Statistical signiﬁcance was assumed for p < 0.05.2.8. Microvessel density
Microvessel density (MVD) was determined by using a monoclonal antibody
against the endothelial cell marker CD31. In ﬁve animals of each group, the left
lateral third of the surviving ﬂap areawas shock frozen in liquid nitrogen and stored
at 80 C afterward. For immunohistochemical investigations 5 mm thick sections
were cut from the snap-frozen tissue and mounted on coated slides provided by
Dako (DAKO REAL, cat# S2024, Germany). Immunohistochemistry was performed
semi-automatically using VENTANA Benchmark XT, Strasbourg, France. For CD31
detection the mouse anti-rat CD31 antibody by Serotec (cat# MCA 1334 GA) was
used in a dilution of 1:50. No antigen retrieval was necessary prior to primary
antibody exposure for 32 min at 37 C. Primary antibody binding sites were visu-
alized using the ultra View Universal DAB Detection Kit by VENTANA/Roche, Man-
nheim, Germany (cat# 760e500). Nuclei were automatically counterstained
implementing hematoxylin (cat# 760-2021) and Bluing Reagent (cat# 760-2037)
provided by VENTANA/Roche, Mannheim, Germany. Following immunohisto-
chemistry, slides were treated in compliance to standard histological methods for
ﬁxation.
From each specimen 3 representative digital images of CD31 stained skin ﬂap
sections were captured at 400magniﬁcation (high power ﬁeld, HPF) using a pho-
tomicroscope (BX-51. Olympus, Tokio, Japan). Morphometric studies were facilitated
by analysis software, cellF, by Olympus, Tokio, Japan. Two independent observers
assessed microvessel density by enumerating the number of CD31-positive vessels
in consecutive three HPF across each central tissue section.
2.9. VEGF
In ﬁve specimens of each group, tissue samples for VEGF quantiﬁcation were
immediately snap-frozen in liquid nitrogen after harvesting and then stored
at 80 C. Total protein content of VEGF in homogenized skin samples was
measured by ELISA using a commercially available kit (rat Quantikine, R&D Systems,
Minneapolis, MN, U.S.) according to the manufacturer’s instruction. Concentration
was expressed as picograms of VEGF per milligram of total protein in the sample.
2.10. Statistical analysis
All values were expressed as the mean  1 standard deviation (SD). Statistical
analysis was performed with non-parametric statistical hypothesis test (Man-
neWhitneyeWilcoxon two sample test). Statistical signiﬁcance was set at p < 0.05.
Results are presented in box-plots with the box representing the inter-quartile range
and the line within the box being the median. Vertical lines represent the 5-to-95
quantile.
3. Results
Seven days after ﬂap harvesting, full-thickness necrosis was
fully developed in each rat. Results are summarized in Table 1. No
animal was excluded from the study due to death, infection, seroma
or autocannibalism.
The mean surviving area in the treatment group was
59.43  14.72% compared to 42.71  10.75% in the control group.
This difference was proven statistically signiﬁcant (p ¼ 0.026)
(Fig. 1a).
The mean perfused area, measured by detection of an intra-
vascular ﬂuorescent, was 62.00  8.58% in the ESWT group (E7)
when compared to 45.14  10.50% the control group. This differ-
ence was also proven to be statistically signiﬁcant (p ¼ 0.007)
(Fig. 1b).
Vessel density, representing the visible vessels per high power
ﬁeld, was 18.13  5.11 vessels/HPF in the ESW-group, compared to
11.09  1.12 vessels/HPF in the control group. Again, this difference
was statistically signiﬁcant (p ¼ 0.016) (Fig. 1c).Vessel density VEGF to total protein
n n
% 5 11.09  1.12 5 0.0123  0.0069
5 18.13  5.11 5 0.2107  0.0935
0.016 0.008
Fig. 1. aed: Diagrams showing (a) the percentage of the clinically visible mean
surviving area, (b) the percentage of the mean perfused area, (c) the mean number of
vessels per high power ﬁeld and (d) the mean ratio of VEGF to total protein concen-
tration 7 days after full ﬂap harvest in the ESWT group compared to the control group.
Fig. 2. Characteristic sample of clinically surviving area 7 days after ﬂap preparation.
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was signiﬁcantly higher in the treated tissue compared to in the
control group (0.2107  0.0935.versus 0.0123  0.0069; p ¼ 0.008)
(Fig. 1d).
Representative views of the aspects of the different groups are
shown in Figs. 2e4,
4. Discussion
Skin ﬂap necrosis in distal ﬂap areas is still a major challenge in
reconstructive surgery and several techniques have been describedFig. 3. Characteristic sample of perfused area 7 days after ﬂap preparation.
Fig. 4. Characteristic sample of vessel density 7 days after ﬂap preparation.
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tissues. Previous animal studies suggested that ESW treatment has
a positive effect in rescuing ischemic zone of ﬂap by an increase of
tissue perfusion.18,19,22,25e27 However, all these studies applied
ESW immediately after the surgical intervention. In a previous
study we were be able to show that preoperative ESWT signiﬁ-
cantly enhances skin ﬂap survival in an epigastric rat skin model,
while the bio-mechanisms operating during preoperative ESWT
remained unclear.20 The presented skin ﬂap survival rate in this
study illustrates that preoperative ESWT has produced reproduc-
ible signiﬁcant results without exception. Furthermore we were
able to show that ﬂap perfusion, microvessel density and VEGF to
total protein ratio were signiﬁcantly elevated in the ESWT group.
Yan et al. described chronological effects for ESWT and distin-
guished early and late effects in a rodent random-pattern skin ﬂap
model.28 The early beneﬁts were subdivided into vasodilatation
and an increased expression of angio-active factors such as NO and
VEGF. The late stage was characterized by a signiﬁcant increase of
both visible collateral vessels and microvessel density. The authors
concluded that an increased blood supply at early stage provided
the ﬂap with a minimum of nutrition and oxygen to keep the
ischemic ﬂap tissue alive until the formation of new vessels. In
agreement with these ﬁndings and other previous studies we
demonstrated that preoperative ESWT resulted in a statistically
signiﬁcant increase of ﬂap survival and perfusion when compared
to the control group. Concordant with these results we measured
a signiﬁcantly higher expression of VEGF in the ESWT group.
Furthermore we found a signiﬁcant increase in vessel density
strongly arguing for neovascularization. According to our ﬁndings
we presume that an increase in blood supply after ESWT could be
mainly attributed to vasodilatation and opening of pre-existing
vessels and thus provide the minimum requirement of oxygen and
nutrition for ischemic tissue. Hence, the early expression of angio-
active factors like NO and VEGF may be the reason for vasodilata-
tion of pre-existing vessels at early post-operative stage and
neovascularization at later stage.
Despite our promising results, several limitations should be
mentioned. First, up-regulation of VEGF was only measured at day
7 postoperatively. For better understanding of the mechanisms
involved in preoperative ESWT, tissue perfusion and growth factor
expression should be examined at earlier time points to clarify the
improvement in tissue viability due to increased VEGF expression
and tissue perfusion. Second, our experimental model did not
distinguish between increased vessel density originating in de novo
blood vessel formation from increased vessel density rooting in the
pre-existing vascular network. Third, our decision for selecting dayseven preoperatively to evaluate the effect of the ESWT was based
on previous studies by Holzbach et al. who in one study deﬁned the
optimal length of surgical delay.20 Therefore the precise mecha-
nism and timing of preoperative ESWT remains to be examined in
further studies.
Our results demonstrate that preoperative ESWT enhances
ischemic tissue survival, blood ﬂow and neovascularization in a rat
skin ﬂap model. The same effect was observed with ESWT imme-
diately after ﬂap surgery. Based on our ﬁndings in this study, we
conclude that preoperative ESWTmay have beneﬁts for therapeutic
ﬂap surgery in clinical practice. Thus, ESWT could be easily
administered on the area of interest, a few days before the surgical
procedure without any risk for the treated tissue and no necessity
of wound management. Moreover it may be of great beneﬁt in
more complex clinical situations with a patient population whose
vascular conditions are frequently insufﬁcient due to Diabetes or
arterial occlusive disease. Preoperative ESWT is easily applicable,
non-invasive, less time-consuming and far more cost-effective
compared with other known surgical and nonsurgical pre-
conditioning techniques.
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